Skip to content

Myobloc / Neurobloc

Myobloc / Neurobloc is the main commercial botulinum toxin type B brand node in this index. The U.S. product name is Myobloc, and its nonproprietary name is rimabotulinumtoxinB. Neurobloc was the corresponding European brand name, though European Medicines Agency materials describe that authorization as withdrawn.

Its role is therapeutic type B reference, not aesthetic type A peer to Botox, Dysport, Xeomin, Jeuveau, Daxxify, or Letybo.

FieldReference point
U.S. brandMyobloc
Other regional nameNeurobloc
Nonproprietary nameRimabotulinumtoxinB
Toxin typeBotulinum toxin type B
Manufacturer / company contextSupernus Pharmaceuticals current company context; Solstice Neurosciences and US WorldMeds history
Main comparison anchorBotulinum toxin type A vs type B

Current U.S. interpretation should stay anchored to Myobloc prescribing information. The product is relevant to therapeutic discussion, especially cervical dystonia and chronic sialorrhea, rather than to the U.S. aesthetic type A comparison set.

Type B biology also affects how readers interpret mechanism, onset discussion, adverse-event framing, and immunogenicity. Those topics require product-specific evidence rather than assumptions from type A products.

Myobloc / Neurobloc keeps the brand map from treating botulinum toxin as only a type A aesthetic category. It gives readers a concrete product-level reference for type B and helps explain why serotype matters.

The type B role does not make Myobloc a direct unit or dose comparator for Botox, Dysport, Xeomin, Jeuveau, Daxxify, or Letybo. Type A and type B products use different biological targets and product-specific potency systems.

Supernus Pharmaceuticals supplies the current company and portfolio context. Botulinum toxin explains the broader medicine family, while type A vs type B and botulinum toxin type B provide the most relevant serotype context.